Fondaparinux vs enoxaparin

(579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent]; hazard ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13), satisfying the

Anticoagulants and antiplatelets aspirin dipyridamole clopidogrel ticlid enoxaparin dalteparin fondaparinux dabigatran

Fondaparinux (Arixtra, GlaxoSmithKline) is as effective as enoxaparin (Lovenox, Sanofi-Aventis) in reducing the risk of ischemic events

Mehta summarized. Among patients who were treated for shorter periods, about 30% fewer bleeding episodes occurred with fondaparinux vs. enoxaparin. It doesn't

and avoid Fondaparinux. High Risk. Encourage ambulation if not Enoxaparin vs heparin for prevention of deep-vein thrombosis in

by AGG Turpie 2024 Cited by 100incidences of efficacy end points with enoxaparin and fondaparinux were 3.3% and 1.7%, Fondaparinux vs enoxaparin for the prevention of venous

Fondaparinux could be a better option vs Enoxaparin, especially in NSTEMI patients, in terms of short to mid-term bleeding risk. Comparison of Efficacy, Safety and Hemostatic Parameters of Enoxaparin and Fondaparinux in unstable coronary artery disease

When PCI was performed 6 h of the last enoxaparin subcutaneous dose, the rates of abrupt closure and threatened abrupt closure did not differ between the enoxaparin and fondaparinux groups (5.9% fondaparinux alone vs. 6.2% enoxaparin alone, HR 0.96, 95% CI 0.73 to 1.26, p = 0.78); however, there was a large reduction in vascular access site

2024 Cited by 1503First, in the short term, fondaparinux and enoxaparin have similar efficacy. Second, as compared with enoxaparin, fondaparinux substantially reduces bleeding.